ERK结合GSK-3β使其失活导致β-catenin表达的上调

来源 :中国肿瘤生物治疗杂志 | 被引量 : 0次 | 上传用户:seraphim
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
β-catenin是一种癌基因,在人类诸多肿瘤中高表达。肝细胞癌(HCC)是人类最多发的恶性肿瘤之一,慢性乙型肝炎病毒(HBV)携带者HCC发病的概率比非携带者高出100倍以上。本文所报道的就是有关HBV-X蛋白(HBX)如何导致β-catenin上调的机制。研究发现,被HBX激活的ERK通过与GSK-3β的一个结合序列结合并磷酸化GSK-3β的43苏氨酸位点,从而启动GSK-3β使其SER9被p90RSK磷酸化,最终导致GSK-3β的失活以及β-catenin的上调。 β-catenin is an oncogene that is highly expressed in many human tumors. Hepatocellular carcinoma (HCC) is one of the most malignant tumors in human. The incidence of HCC in patients with chronic hepatitis B virus (HBV) is more than 100 times higher than that of non-carriers. What is reported in this paper is about how HBV-X protein (HBX) causes the upregulation of beta-catenin. It has been found that activation of HBX by ERK activates GSK-3β by binding to a binding sequence of GSK-3β and phosphorylating the 43 threonine site of GSK-3β to phosphorylate SER9 by p90RSK, eventually leading to GSK-3β Inactivation and up-regulation of β-catenin.
其他文献
近年来我国婴幼儿先天性心脏病(CHD)外科治疗得到快速发展,治疗水平明显提高,主要体现在以下几个方面.  一、婴幼儿比例渐增,年龄渐小,疗效明显提高[1]